The DOI matches its Crossref record.
Intravenous carboplatin for recurrent malignant glioma: a phase II study.
Abstract
Thirty patients with recurrent malignant glioma were treated with intravenous (IV) carboplatin (CBDCA) every 4 weeks at a starting dose of 400 mg/m2 escalating to 450 mg/m2. All patients had documented recurrent tumor after prior radiotherapy but had not received prior chemotherapy. Of 29 assessable patients, four (14%) responded to the treatment for 44, 51+, 72, and 91 weeks; 10 (34%) achieved stable disease (S); while 15 (52%) had progressive disease (P). The total response (responses plus S) rate was 48%, with a median time to progression (MTP) of 26 weeks in these patients; the MTP for all 29 patients was 11 weeks. The toxic effects were mainly hematologic, with thrombocytopenia and granulocytopenia being mild at 400 mg/m2 and 450 mg/m2 doses. NO neurotoxicity or renal toxicity was encountered. These results suggest that CBCDA given at 400 mg/m2 or 450 mg/m2 every 4 weeks is marginally active in patients with recurrent malignant gliomas. Since hematologic toxicity is mild, a higher dose could possibly be given, and may increase the response rate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fine, H. A., Dear, K. B. G., Loeffler, J. S., Mc Black, P. L., & Canellos, G. P. (1993) · Cancer · doi:10.1002/1097-0142(19930415)71:8<2585::aid-cncr2820710825>3.0.co;2-s · Cited by 864
Yung, W. K. A., Prados, M. D., Yaya-Tur, R., Rosenfeld, S. S., Brada, M., Friedman, H. S., Albright, R., Olson, J., Chang, S. M., O'Neill, A. M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2762 · Cited by 761
Self-citationClinical trial of blood-brain barrier disruption by pulsed ultrasound
Carpentier, A., Canney, M., Vignot, A., Reina, V., Beccaria, K., Horodyckid, C., Karachi, C., Leclercq, D., Lafon, C., Chapelon, J.-Y., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6086 · Cited by 757
Guillaume, D. J., Doolittle, N. D., Gahramanov, S., Hedrick, N. A., Delashaw, J. B., & Neuwelt, E. A. (2010) · PubMed · doi:10.1227/01.neu.0000363152.37594.f7 · Cited by 420
Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma
Stupp, R., Hegi, M. E., van den Bent, M. J., Mason, W. P., Weller, M., Mirimanoff, R. O., Cairncross, J. G., & on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-165 · Cited by 373
Metadata
- Authors
- Yung, W. K., Mechtler, L., & Gleason, M. J.
- Venue
- Journal of Clinical Oncology
- Published
- 1991-05
- Volume
- 9
- Issue
- 5
- Pages
- 860-864
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1944104521
- Cited by
- 179
- References
- 0
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravenous carboplatin for recurrent malignant glioma: a phase II study. https://app.cochat.ai/papers/10.1200/jco.1991.9.5.860
- The paper
- Yung, W. K., Mechtler, L., & Gleason, M. J. (1991). Intravenous carboplatin for recurrent malignant glioma: a phase II study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1991.9.5.860
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.